PFAS in Drug Manufacturing: An Emerging Quality and Environmental Issue
The pharmaceutical industry’s relationship with fluorine chemistry is deep and multifaceted. Approximately 20% of approved drugs contain at least one C-F bond—including blockbusters like atorvastatin (Lipitor), fluoxetine (Prozac), ciprofloxacin, and many psychiatric, cardiovascular, and oncology compounds. This intentional use of fluorine in API structure is pharmacologically deliberate—C-F bonds improve metabolic stability, bioavailability, and receptor binding. Distinct from API chemistry, pharmaceutical manufacturing processes use PFAS in equipment coatings, gaskets, seals, and process aids that can contribute trace PFAS to finished drug products—an unintentional contamination pathway increasingly scrutinized by FDA and EMA.
FDA Guidance on PFAS Leachables in Drug Products
FDA’s guidance on container/closure system safety (2019) and elemental impurities (ICH Q3D) provide frameworks for evaluating extractable and leachable substances from manufacturing equipment that contact drug products. PTFE-lined vessels, PTFE gaskets, and fluoropolymer tubing used in parenteral drug manufacturing have been identified as sources of trace PFAS leachables in drug products—particularly in water-for-injection, injectable biologics, and sterile liquid formulations. FDA’s 2023 draft guidance on PFAS in pharmaceutical manufacturing specifically addresses: analytical methods for PFAS leachables; thresholds of toxicological concern (TTC) for PFAS in drug products (proposed 1 ng/day safety threshold for perfluorocarboxylic acids); equipment qualification requirements for PFAS-containing manufacturing systems; and disclosure requirements for PFAS leachables in regulatory submissions.
API Manufacturing Wastewater: A PFAS Source
Active pharmaceutical ingredient (API) manufacturing using fluorination chemistry generates PFAS-containing wastewater from reactions, solvent recovery, and equipment cleaning. Indian pharmaceutical manufacturing clusters (Hyderabad’s API manufacturing corridor, Vadodara’s pharma zone) produce a significant fraction of global API supply and discharge process wastewater to industrial effluent treatment systems of variable quality. A 2022 study of Hyderabad’s Musi River—receiving pharmaceutical manufacturing wastewater—found PFAS at 5–20 ng/L associated with fluorination chemistry facilities. Chinese API manufacturing (Taizhou, Linhai pharmaceutical industrial zones) similarly contributes PFAS to local water bodies through pharmaceutical process wastewater. EU and FDA Good Manufacturing Practice (GMP) regulations require PFAS characterization in API manufacturing submissions for processes using PFAS reagents or equipment.
Fluorinated Drug Metabolites: The Environmental Persistence Question
The C-F bonds in fluorinated drugs create their own environmental PFAS issue: pharmaceuticals excreted by patients—through urine and feces—enter municipal wastewater treatment systems as partially metabolized fluorinated compounds. These metabolites may retain perfluorinated or polyfluorinated structural elements that are recalcitrant to biological treatment. Research is at an early stage, but HPLC-HRMS studies of WWTP effluent have detected fluorinated pharmaceutical metabolites at ng/L concentrations alongside conventional PFAS. Whether these compounds meet regulatory definitions of PFAS and what their environmental fate and health significance are remains an active area of investigation—potentially expanding the PFAS regulatory universe to include pharmaceutical metabolites.
The intersection of PFAS and pharmaceuticals reveals that fluorine chemistry pervades both therapeutic innovation and industrial processes—requiring nuanced regulatory approaches that distinguish between intentional therapeutic fluorine use and unintentional PFAS contamination in drug manufacturing.